Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug – DG Verifications & Stats

Open the article to view the coverage from Busines and Oil News

Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial

Pfizer announced it would be acquiring Metsera for $4.9bn earlier in September 2025.The post Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial appeared first on Clinical Trials Arena.

Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer

Pfizer’s back in obesity. Or is it? The hotly-awaited Phase 2b readout of the long-acting GLP-1 shot developed by Metsera, the biotech Pfizer said it would buy for $4.9 billion last week ...